Trevor, a 36-year-old graphic designer in Portland, Oregon, ordered psilocybin mushrooms from a state-licensed service center in early 2026 and began a microdosing protocol his community group called “Stamets stack.” Three days on, four days off, 0.15 grams per dose. He had been on bupropion for two years with partial response. His PHQ-9 hovered at 11. After six weeks of microdosing, his self-reported scores dropped to 7. He attributed the change to the mushrooms. His psychiatrist, who he had told about the experiment, was less certain. The placebo response in microdosing trials is enormous. Trevor’s improvement coincided with starting a new design contract he loved, joining a hiking group, and switching to a standing desk. Untangling those variables in a single user is impossible. Trevor’s story is one face of a national experiment that is happening with or without medical supervision, and the questions it raises about microdosing psychedelics deserve a careful, evidence-first answer.
What microdosing psychedelics actually means
Microdosing refers to the regular consumption of psychoactive substances at sub-perceptual doses, typically one-tenth to one-twentieth of a recreational dose. For psilocybin, that means roughly 0.1 to 0.3 grams of dried Psilocybe cubensis mushrooms, compared to a typical psychoactive dose of 2-5 grams. For LSD, microdoses are 8 to 15 micrograms versus 100-200 micrograms for a full experience. The user is not supposed to feel high, hallucinate, or be impaired. The intended effect is a subtle improvement in mood, creativity, or focus while functioning normally at work and in relationships.
Schedules vary. Paul Stamets’s “Stamets stack” pairs microdose mushrooms with niacin and lion’s mane mushroom on a 4-on-3-off schedule. James Fadiman, often credited with reviving research interest in microdosing, recommends a 1-day-on-2-days-off rotation. Some users dose daily. The schedules are largely empirical. Tolerance to psilocybin builds quickly, which is the main pharmacological reason every-other-day or less-frequent dosing has emerged as standard practice.
Federal Schedule I status and state-level decriminalisation
Psilocybin remains a Schedule I substance under the federal Controlled Substances Act, meaning the DEA classifies it as having no accepted medical use and high abuse potential. Possession is a federal crime regardless of state law. Federal prosecutors have generally focused on large-scale distribution rather than personal use, but the legal exposure is real and uneven across jurisdictions.
State-level patchwork has emerged in three forms:
- Oregon Measure 109 (2020) created a regulated psilocybin services framework that allows licensed administration in service centres for adults 21 and older, with the first centres opening in 2023
- Colorado Proposition 122 (2022) decriminalised personal possession of psilocybin and authorised supervised “healing centers” beginning in 2024-2025
- City-level decriminalisation has occurred in Denver, Oakland, Santa Cruz, Washington DC, Seattle, Detroit, Cambridge, Somerville, Northampton, Easthampton, Ann Arbor, and several others, generally making enforcement the lowest priority for local police
None of these state laws override federal law. They create local enforcement deprioritisation and, in Oregon and Colorado, a regulated service-center pathway. Importing mushrooms across state lines remains a federal crime. Possession on federal land (national parks, federal buildings) is enforced under federal statutes. The legal landscape changes frequently; check current local statutes before assuming a practice is permitted.
What the placebo-controlled trials show
The most rigorous microdosing data come from a 2021 self-blinding study published in eLife by Balázs Szigeti and colleagues at Imperial College London. Participants prepared their own capsules following an elaborate randomisation protocol that allowed for true blinding. Both microdose and placebo groups improved significantly on psychological measures. The microdose group did not outperform placebo on any primary endpoint. The authors concluded that the perceived benefits of microdosing are likely placebo effects.
A 2022 study by Polito and Stevenson, also self-blinded, reached similar conclusions. A 2023 University of Chicago laboratory study using moderately controlled doses found very small acute effects on mood that did not exceed placebo when both arms were properly blinded. The pattern is consistent: open-label microdosing produces large reported improvements; properly blinded microdosing produces effects indistinguishable from placebo.
This does not mean nobody benefits. Placebo effects are real psychological phenomena, and a six-week ritual involving capsule preparation, self-monitoring, and engagement with a community of similarly motivated people would predictably produce mood improvement even if the substance had no specific pharmacological effect at the studied dose.
Macrodose research is different
The evidence base for full psychoactive doses (macrodoses) of psilocybin combined with psychotherapy is genuinely promising. Imperial College London’s 2021 trial published in NEJM compared psilocybin-assisted therapy to escitalopram and showed comparable efficacy on the primary endpoint. Johns Hopkins research led by Roland Griffiths showed sustained reductions in depression and anxiety in patients with cancer-related distress after one or two high-dose sessions. The Usona Institute and Compass Pathways have conducted phase 2 and phase 3 trials in treatment-resistant depression with response rates that approach what good antidepressants achieve.
The FDA granted breakthrough therapy designation to Compass Pathways’ psilocybin formulation (COMP360) for treatment-resistant depression in 2018 and to Usona’s formulation in 2019. Approval pathways depend on phase 3 results, which are still being evaluated. The macrodose pathway involves preparation sessions, an 8-hour dosing session with two trained facilitators, and integration sessions afterward. It is fundamentally different from at-home microdosing in dose, supervision, and intent. Conflating the two is the most common error in popular reporting.
Valvular heart disease and other safety concerns
The most concrete safety concern with chronic psychedelic dosing is potential effects on cardiac valves. Psilocin (the active metabolite of psilocybin) has affinity for the 5-HT2B receptor expressed on heart valve fibroblasts. Drugs with strong 5-HT2B agonism, including the discontinued diet drug fenfluramine and methylergonovine, have produced valvulopathy with chronic exposure. The 5-HT2B affinity of psilocin is meaningful but lower than that of fenfluramine, and the dosing schedules used in approved trials are intermittent, which reduces theoretical risk.
Daily microdosing for months or years has not been studied for valvular safety. Several research groups have flagged this as the most plausible mechanism by which microdosing could produce harm. Anyone considering chronic dosing should be aware of this concern. People with pre-existing valvular disease should not microdose. Echocardiogram surveillance is not standard practice for microdosers and probably should be for those continuing the practice for over a year. Other concerns include serotonin syndrome risk in users on SSRIs/SNRIs, particularly at the upper end of microdose ranges where pharmacological effects emerge.
FDA breakthrough designation and the regulatory landscape
The US Food and Drug Administration has granted breakthrough therapy designations to several psychedelic compounds for specific indications. Compass Pathways is conducting late-stage trials of synthetic psilocybin (COMP360) for treatment-resistant depression. MAPS (Multidisciplinary Association for Psychedelic Studies) submitted MDMA-assisted therapy for PTSD; the FDA declined approval in 2024 and requested additional studies. Usona Institute is advancing psilocybin for major depressive disorder.
None of these regulatory pathways involves microdosing. The approved (or potentially approved) protocols are for full-dose, supervised therapy with specific clinical training requirements. If a future psilocybin product reaches the market, it will not be a daily home medication. The FDA approval framework would create a clinical pathway distinct from the recreational and self-experimental microdosing that dominates current consumer practice. Patients with severe trauma considering this pathway might also explore trauma residential PTSD programs that combine evidence-based therapies with intensive support.
Ketamine clinics as the legal alternative
For patients with treatment-resistant depression who are interested in a psychedelic-adjacent intervention with legal infrastructure, ketamine and esketamine (Spravato) are the clear answer in 2026. Ketamine acts on NMDA receptors rather than 5-HT2A and produces a dissociative experience at therapeutic doses. Spravato is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Off-label IV ketamine is widely available through specialty clinics. Both work through different mechanisms than psilocybin but produce similarly rapid antidepressant effects in many patients.
Ketamine therapy is covered by some insurance for the FDA-approved indication and is offered through clinics in most US metropolitan areas. Our overview of Spravato clinics walks through the protocol, eligibility, and what to expect. For someone weighing microdosing against an established legal option, the ketamine pathway has clearer evidence, supervised administration, and insurance coverage that microdosing lacks.
Drug interactions that matter
Patients on psychiatric medications considering microdosing face several interaction concerns:
- SSRIs and SNRIs can blunt the effect of psilocybin (the rationale used to justify microdosing while continuing them) but also raise theoretical risk of serotonin syndrome at higher microdose ranges
- MAOIs combined with psilocybin can produce dangerously prolonged and intensified effects
- Lithium plus psilocybin has been associated with seizure reports
- Tramadol can lower seizure threshold and should not be combined
- Stimulants amplify cardiovascular effects
Patients tapering off antidepressants to microdose should not stop medication abruptly. Our guide to tapering antidepressants covers the evidence-based approach to discontinuation, which still applies regardless of what comes next.
The harm reduction reality
Tens of thousands of Americans are microdosing in 2026 regardless of legal status or evidence base. Pretending the practice does not exist is not useful clinical guidance. From a harm-reduction perspective, the practical advice for someone who has decided to proceed includes:
- Test substances for purity using reagent kits, particularly for synthetic compounds
- Start with the lowest dose (0.05-0.1 g psilocybin) to assess individual sensitivity
- Use a 1-on-2-off schedule rather than daily dosing
- Take a complete break of at least one month every 6 months
- Inform your psychiatrist or primary care doctor; they cannot help you stay safe if they do not know
- Avoid combining with alcohol, cannabis at the same time, MAOIs, lithium, or tramadol
- Track mood and side effects; if scores worsen rather than improve, stop
- Have a sober person available during the first dose in case the response is stronger than expected
The National Institute on Drug Abuse publishes information on hallucinogen use and emerging research that can be useful for clinicians and patients trying to evaluate evolving evidence.
Frequently asked questions about microdosing
Will microdosing show up on a drug test?
Standard 5-panel and 10-panel workplace drug tests do not screen for psilocybin. Specialised hallucinogen panels can detect psilocin metabolites for 24-48 hours. Hair tests may detect use over longer windows. Federal employees, transportation workers, and others subject to specialised testing should not assume they are safe.
Is microdosing addictive?
Psilocybin has very low addictive potential by traditional measures: it does not produce physical dependence, withdrawal is not characteristic, and tolerance builds rapidly enough to limit daily use. Psychological reliance can develop. People may struggle to stop a practice they associate with mood improvement, even when the evidence suggests benefit is placebo-mediated.
Can I get microdoses prescribed?
No. As of 2026, no psychedelic compound is FDA-approved for any indication, microdose or otherwise. Oregon’s psilocybin services framework is not a prescription pathway and does not involve physicians as prescribers. Compounds available through clinical trials are dosed at psychoactive levels, not microdoses.
What about mescaline or DMT microdosing?
Both are Schedule I federally. The evidence base is even thinner than for psilocybin or LSD. DMT’s short half-life makes meaningful microdosing logistically difficult; ayahuasca microdosing has emerged in some communities but lacks any controlled study. Mescaline microdosing has anecdotal advocates but no rigorous trial data.
Should I tell my therapist?
Yes. A therapist who does not know what you are taking cannot accurately interpret changes in your mental state, side effects, or treatment response. Most therapists will not report you to authorities for personal use disclosed in a clinical setting. If your therapist responds with judgment rather than clinical engagement, that is information about whether the relationship is the right fit.
The bottom line
Microdosing psychedelics is legal in two states with regulated infrastructure, decriminalised in roughly a dozen cities, and federally illegal everywhere. The placebo-controlled evidence does not support specific pharmacological benefit at sub-perceptual doses. The macrodose evidence for psilocybin-assisted therapy is genuinely promising for treatment-resistant depression but represents a different clinical model entirely. People who proceed with microdosing should be aware of valvular safety concerns, drug interactions, and the gap between what the science actually shows and what wellness marketing claims. Ketamine clinics offer the closest legal alternative for patients seeking a psychedelic-adjacent intervention with established evidence and infrastructure.
If you are in crisis, call or text 988 for the Suicide and Crisis Lifeline.
This article is for educational purposes only and is not legal, medical, or mental health advice. Possession of psilocybin and LSD remains illegal under federal law and in most US states. Drug interactions can be dangerous; consult a qualified clinician before changing psychiatric medications or beginning any psychedelic practice.